Gilead Sciences, Inc. (NASDAQ:GILD) Expected to Post Earnings of $1.73 Per Share

Equities analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILDGet Rating) will post earnings of $1.73 per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.86 and the lowest is $1.38. Gilead Sciences reported earnings per share of $2.08 during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.8%. The business is scheduled to announce its next earnings report on Monday, January 1st.

On average, analysts expect that Gilead Sciences will report full-year earnings of $6.51 per share for the current year, with EPS estimates ranging from $6.22 to $6.94. For the next year, analysts expect that the company will report earnings of $6.32 per share, with EPS estimates ranging from $4.97 to $6.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Gilead Sciences.

Gilead Sciences (NASDAQ:GILDGet Rating) last posted its quarterly earnings results on Tuesday, February 1st. The biopharmaceutical company reported $0.69 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.53 by ($0.84). The firm had revenue of $7.24 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a net margin of 22.80% and a return on equity of 45.27%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.19 EPS.

Several brokerages have recently issued reports on GILD. BMO Capital Markets began coverage on Gilead Sciences in a report on Tuesday, March 8th. They issued a “hold” rating and a $65.00 price objective for the company. Barclays decreased their price objective on Gilead Sciences from $63.00 to $56.00 and set an “underweight” rating for the company in a report on Thursday, March 10th. Mizuho decreased their price objective on Gilead Sciences from $81.00 to $75.00 and set a “buy” rating for the company in a report on Tuesday, February 8th. Maxim Group decreased their price objective on Gilead Sciences from $88.00 to $84.00 in a report on Thursday, February 3rd. Finally, Wells Fargo & Company decreased their price objective on Gilead Sciences from $70.00 to $63.00 and set an “equal weight” rating for the company in a report on Tuesday, March 22nd. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $73.31.

In other news, EVP Brett A. Pletcher sold 1,691 shares of the company’s stock in a transaction that occurred on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders sold 19,386 shares of company stock valued at $1,283,423 over the last 90 days. Company insiders own 0.16% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Wolf Group Capital Advisors grew its position in Gilead Sciences by 200.0% in the fourth quarter. Wolf Group Capital Advisors now owns 128,271 shares of the biopharmaceutical company’s stock worth $9,314,000 after acquiring an additional 85,514 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $8,758,000. Cpwm LLC grew its stake in shares of Gilead Sciences by 24.6% in the third quarter. Cpwm LLC now owns 31,240 shares of the biopharmaceutical company’s stock valued at $2,182,000 after buying an additional 6,163 shares in the last quarter. WBI Investments Inc. grew its stake in shares of Gilead Sciences by 10.4% in the fourth quarter. WBI Investments Inc. now owns 46,422 shares of the biopharmaceutical company’s stock valued at $3,249,000 after buying an additional 4,371 shares in the last quarter. Finally, Meyer Handelman Co. grew its stake in shares of Gilead Sciences by 0.9% in the third quarter. Meyer Handelman Co. now owns 423,424 shares of the biopharmaceutical company’s stock valued at $29,576,000 after buying an additional 3,900 shares in the last quarter. Institutional investors own 79.00% of the company’s stock.

Shares of GILD stock opened at $61.82 on Tuesday. The stock has a market cap of $77.52 billion, a PE ratio of 12.54, a price-to-earnings-growth ratio of 0.44 and a beta of 0.40. The business has a 50-day simple moving average of $60.52 and a 200-day simple moving average of $66.17. The company has a quick ratio of 1.13, a current ratio of 1.27 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $57.19 and a 52-week high of $74.12.

The business also recently declared a quarterly dividend, which was paid on Wednesday, March 30th. Stockholders of record on Tuesday, March 15th were given a $0.73 dividend. The ex-dividend date was Monday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.71. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio is 59.23%.

Gilead Sciences Company Profile (Get Rating)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

See Also

Get a free copy of the Zacks research report on Gilead Sciences (GILD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.